OMRON Healthcare Remote Patient Monitoring Services Win “Best of” Honors at CES 2022
21.1.2022 18:21:00 EET | Business Wire | Press release
OMRON Healthcare, Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S:
- Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE, Residential Systems and TechRadar Pro Picks Awards
- VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection
These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes.
“OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke,” said Andre Van Gils, senior general manager, global sales & marketing and executive officer of OMRON Healthcare Corporation Ltd. - Japan.
Hypertension Plus is designed to help NHS clinicians manage a patient’s medication plan remotely, based on the patient’s home blood pressure results submitted through its dedicated mobile app. The platform generates tailored medication plans for patients, which are then adjusted by clinicians as necessary. Patients are then informed immediately over the dedicated mobile app, connecting them directly to their physician. Automated reminders and scheduled condition management actions keep the patient engaged in treatment. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and informs clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. All of these recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines, and developed by Oxford university.
In addition to CES, Hypertension Plus has also been recognised by ORCHA (the Organisation for the Review of Care and Health Applications) and Dorset Clinical Commission Group (CCG) on their leading UK-recognised health and care app review portal, with Hypertension Plus currently the highest rated application for hypertension.
In their annual rankings, TWICE, Residential Systems , and TechRadar Pro Picks Awards honor the best and most influential consumer technology. The TWICE Picks Awards Winners 2022 were chosen based on the impact that they are expected to have on the consumer electronic and retail Industries. To see the full list, visit TWICE , Residential Systems or TechRadar Pro .
VitalSight is the first remote patient monitoring service from OMRON Healthcare, an easy-to-use service that a physician can offer to patients with high-risk levels of hypertension. Patients receive a kit delivered to their home that includes an OMRON connected blood pressure monitor and data hub that are pre-set to securely share measurements – digitally – with the patient’s physician and care team. The VitalSight data hub, which can be used at home without Wi-Fi or cellular connection, received attention at CES for bridging health care gaps for patients in under-resourced communities.
Insider recognised VitalSight by OMRON on its list of 13 most exciting health, home and kitchen products of CES 2022. The list brought together high-tech concepts and new products – unveiled at CES 2022 – that you can buy now or later in 2022. Insider cited VitalSight among the “Best of” CES as “life-saving technology” and “great technology for patients who can't see their doctor regularly because of location, finances, or mobility concerns.” To see the full list, visit Insider.
“Our team, fully committed to our Going for Zero mission, worked diligently to create and launch our remote patient monitoring services around the world,” said Van Gils. “We are fortunate to have such dedicated staff and employees who are passionate about empowering people to take charge of their heart health and saving lives. Congratulations to our team on this extraordinary effort.”
To learn more about Remote Patient Monitoring services from OMRON, visit: https://healthcare.omron.com/ces2022
To learn more about OMRON Healthcare, the company’s Going for Zero mission and its innovations, visit omron-healthcare.co.uk, and follow OMRON Healthcare on Twitter and LinkedIn.
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.
Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.
OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.
OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005268/en/
Contact information
Liam Kirkham
Hotwire Global
omronhealthcare@hotwireglobal.com
+44 207 608 4636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom